$0.00 EPS Expected for Trillium Therapeutics (TRIL); Capital International Boosted Enbridge (ENB) Stake

Capital International Inc increased Enbridge Inc (ENB) stake by 53.54% reported in 2016Q4 SEC filing. Capital International Inc acquired 90,700 shares as Enbridge Inc (ENB)’s stock declined 4.32%. The Capital International Inc holds 260,100 shares with $10.96M value, up from 169,400 last quarter. Enbridge Inc now has $64.92B valuation. It closed at $40.5 lastly. It is down 8.41% since September 28, 2016 and is downtrending. It has underperformed by 18.46% the S&P500.

Analysts expect Trillium Therapeutics Inc (TSE:TRIL) to report $0.00 EPS on May, 12. It closed at $8.44 lastly. It is down 58.38% since September 28, 2016 and is downtrending. It has underperformed by 68.43% the S&P500.

Among 13 analysts covering Enbridge Inc. (NYSE:ENB), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Enbridge Inc. has $74 highest and $45 lowest target. $63’s average target is 55.56% above currents $40.5 stock price. Enbridge Inc. had 17 analyst reports since August 4, 2015 according to SRatingsIntel. As per Wednesday, July 20, the company rating was downgraded by Goldman Sachs. As per Monday, July 18, the company rating was downgraded by National Bank Canada. The firm has “Outperform” rating given on Tuesday, March 14 by Credit Suisse. As per Thursday, February 4, the company rating was downgraded by Credit Suisse. Canaccord Genuity initiated the stock with “Buy” rating in Monday, March 7 report. The firm earned “Outperform” rating on Wednesday, March 2 by BMO Capital Markets. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 23. The rating was reinitiated by Citigroup with “Neutral” on Wednesday, January 18. As per Friday, October 9, the company rating was maintained by RBC Capital Markets. Credit Suisse maintained the stock with “Neutral” rating in Tuesday, March 8 report.

Capital International Inc decreased Ctrip.Com Intl Adr (NASDAQ:CTRP) stake by 40,800 shares to 107,546 valued at $4.30M in 2016Q4. It also reduced Tenaris Sa Adr (NYSE:TS) stake by 52,900 shares and now owns 225,646 shares. Enel Chile Sa Adr was reduced too.

Trillium Therapeutics Inc is a Canada clinical stage immuno-oncology firm developing therapies for the treatment of cancer. The company has market cap of $66.21 million. The Company’s SIRPaFc program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It currently has negative earnings. It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.